Association of dietary patterns with all-cause and cause-specific mortality in a high cardiovascular risk population in China.

Postpartum depression (PPD) is a common psychiatric condition affecting women during the puerperium period, primarily characterized by significant depressive symptoms and emotional disturbances. The global prevalence of PPD is estimated to range from approximately 10–15%, with epidemiological data revealing more specific patterns—averaging around 13% in high-income countries while reaching up to 19% in low- and middle-income countries. In China specifically, the prevalence rate stands at approximately 16.3% and has exhibited a concerning upward trend in recent years. The temporal manifestation of PPD typically follows a predictable pattern, with symptoms usually emerging between four and eight weeks postpartum and reaching peak intensity within the first few weeks, although delayed onset can also occur. Notably, research has documented that approximately 7.2% of mothers develop depressive symptoms later, at nine to ten months postpartum. The clinical presentation encompasses a spectrum of symptoms, including fatigue, anxiety, irritability, anhedonia, sleep and appetite disturbances, diminished self-esteem, feelings of parental inadequacy, persistent sadness, guilt, cognitive impairment, and, in severe cases, suicidal ideation. The pathogenesis of PPD involves a complex interplay among neuroendocrine alterations, psychosocial factors, and environmental stressors. Management of postpartum depression necessitates an integrated therapeutic approach that combines pharmacological interventions, psychological treatments, and robust social support systems. Treatment strategies are typically stratified by symptom severity. For mild cases, non-pharmacological interventions such as cognitive behavioral therapy and interpersonal psychotherapy are generally preferred, as these modalities effectively address distorted thinking patterns and enhance adaptive coping mechanisms. In contrast, moderate to severe postpartum depression often necessitates pharmacological treatment with SSRIs combined with psychotherapy, while cases complicated by suicidal ideation or psychotic features require urgent psychiatric referral and, when indicated, intensive interventions such as electroconvulsive therapy (ECT), repetitive transcranial magnetic stimulation (rTMS), or novel FDA-approved agents including brexanolone and zuranolone. Beyond pharmacological approaches, research has increasingly recognized the critical role of caregivers in influencing treatment outcomes and recovery trajectories for women with PPD. Family or primary caregivers are generally understood as unpaid individuals who provide ongoing, close support to someone with health or functional needs, often encompassing physical, emotional, and daily living assistance. Studies have demonstrated that adequate caregiver knowledge and supportive behaviors can significantly enhance treatment adherence, reduce symptom severity, and accelerate recovery from postpartum depression. A systematic review by Dennis and Dowswell found that psychosocial and psychological interventions delivered by caregivers reduced the likelihood of depression persistence by 34% compared to standard care. Furthermore, Letourneau et al. highlighted that caregiver-led supportive interventions yielded comparable efficacy to professional-led interventions for mild to moderate PPD cases, underscoring caregivers’ pivotal function in the therapeutic alliance. A concerning trend emerges from existing evidence, which indicates that caregivers frequently lack adequate skills to identify depressive symptoms and provide appropriate supportive interventions, thereby underscoring the necessity for targeted educational programs. Partner-based support interventions have demonstrated considerable efficacy in Western contexts, with systematic reviews showing that partner involvement can reduce PPD symptom severity by 25–30% and improve treatment adherence.